These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34873979)

  • 1. A 10-year economic analysis of HIV management in Greece: evidence of efficient resource allocation.
    Athanasakis K; Naoum V; Naoum P; Nomikos N; Theodoratou D; Kyriopoulos J
    Curr Med Res Opin; 2022 Feb; 38(2):265-271. PubMed ID: 34873979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs and effectiveness of surveillance of communicable disease: a case study of HIV and AIDS in England and Wales.
    Morris S; Gray A; Noone A; Wiseman M; Jathanna S
    J Public Health Med; 1996 Dec; 18(4):415-22. PubMed ID: 9023800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
    Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
    Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
    PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal access to HIV treatment in developing countries: going beyond the misinterpretations of the 'cost-effectiveness' algorithm.
    Moatti JP; Marlink R; Luchini S; Kazatchkine M
    AIDS; 2008 Jul; 22 Suppl 1():S59-66. PubMed ID: 18664955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
    Johri M; David Paltiel A; Goldie SJ; Freedberg KA
    Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of providing HIV care and optimal allocation of HIV resources in Guyana.
    Suraratdecha C; Stuart RM; Edwards M; Moore R; Liu N; Wilson DP; Albalak R
    PLoS One; 2020; 15(10):e0238499. PubMed ID: 33119591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of methods for estimating the cost of human immunodeficiency virus-testing interventions.
    Shrestha RK; Sansom SL; Farnham PG
    J Public Health Manag Pract; 2012; 18(3):259-67. PubMed ID: 22473119
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.